African Health Sciences
Makerere University Medical School
Vol. 15, No. 2, 2015, pp. 328-333
Bioline Code: hs15050
Full paper language: English
Document type: Research Article
Document available free of charge
African Health Sciences, Vol. 15, No. 2, 2015, pp. 328-333
© Copyright 2015 - African Health Sciences
Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda|
Ocama, Ponsiano; Seremba, Emmanuel; Apica, Betty & Opio, Kenneth
Background: Hepatitis B virus (HBV) and HIV are endemic in Uganda. Co-infection is common and leads to rapid progression
of liver disease. Burden of co-infection is unknown yet most patients are on lamivudine-only ART where resistance
is frequent. Most patients are initiated on antiretroviral therapy (ART) without knowing their HBV status.
Objectives: To determine burden of co-infection and HBV viral suppression among patients on ART in NorthernUganda.
Methods: We recruited HIV infected adult patients on ART in a cross-sectional study. Age, sex, ART regimen and duration
were recorded. Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBcAb) and liver panel were performed.
For those HBsAg+, hepatitis B e antigen (HBeAg) and HBV DNA were performed. CD4 cell count was recorded.
Results: Three hundred patients were recruited. Twenty (6.7%) were co-infected, while 41% were anti-HBcAb+. Overall
188 (62.7%) were on lamivudine- only HBV active drug. Median ART duration 2 years (IQR 1-5), mean CD4+ cell count
317 cells/microlitre (SD 255-557). Of 20 HIV/HBV co-infected, 11/20 (55%) were on lamivudine-only ART, median
duration 1.5 years. Nineteen (95%) had undetectable HBV DNA. Seventeen (85%) were HBeAg negative. Mean CD4+
cell count 327 cells/microlitre (SD 197-482).
Conclusion: A large proportion of patients were on lamivudine- only HBV-active ART. Resistance may occur long term
thus testing for HBV and correct ART is recommended
HIV; HBV; Co-infection; Treatment